



Alcami Corporation, formerly AAIPharma Services Corp. / Cambridge Major Laboratories, Inc.
6200 S. Lindbergh Blvd.
Saint Louis, MO 63123
Re: Quality and Regulatory Affairs Notification

27 March 2017

Dear Customer:

We are pleased to announce the opening of a new world class laboratory facility in St. Louis. The current facility for laboratory operations will be transitioning to a new facility located at 4260 Forest Park Ave., Suite 201, St. Louis, MO 63108. In addition to being located in the innovative Cortex Technology Park, the facility offers numerous state-of-the-art features such as improved backup power generation, new upgraded utilities (i.e. water systems) and IT infrastructure. The new facility layout maximizes space and utilizes improved process flows while offering more lab (Chemistry and Micro) and stability chamber space. We are pleased to bring continued efficiency, quality, and capacity improvements to our clients.

For clarification, this is not a "laboratory site change" such as that associated with the transfer of laboratory operations from one company to another. This is the physical relocation of the current lab operations from one building to another. Current laboratory operations (personnel, the majority of SOP's, most of the equipment, etc.) will remain unchanged. In some instances, older instrumentation will be replaced with new like-for-like instrumentation, and some SOP's will be changed for administrative purposes where the specific address is identified in the procedure. The new site will have the full capability of continued performance of all current testing.

We anticipate starting the transition of current operations to the new facility in the second quarter of 2017. An updated schedule will be provided later this year that will reflect the pace of ongoing construction. Our current plans estimate a transitional phase of approximately 6 months. During this implementation plan, GMP activities will occur at both sites for a short period of time in order to minimize any impact to our customers. The Alcami team will contact you regarding the specific timeline for transition of your services. Alcami is committed to ensuring a smooth transition with no interruption in our services.

The FDA and DEA have been notified on the upcoming move and all appropriate registrations will be updated accordingly. The FDA FEI number for the new facility will not change and will be **1942094**. We are working with Dun & Bradstreet to keep the DUNS number the same. We will provide another written update once that is confirmed. For commercial products, we believe this is a change that can be reported as part of an Annual Report submission.

Alcami is committed to providing the required documents and correspondence needed to support your regulatory activities. We look forward to our continued partnership. If you have questions, please reach out to your primary contact person or myself.

Sincerely,

Brian Dillion - Vice President, Quality and Regulatory